Skip to main content
Premium Trial:

Request an Annual Quote

Upstate Group, CXR Biosciences, Cellomics, Odyssey Thera, Lexicon Genetics, Kalypsys, Scripps Research Institute, Galapagos, Celera Genomics


Upstate Partners with CXR Biosciences
to Develop Drug-Screening Tests

Upstate Group, a Serologicals subsidiary, and CXR Biosciences plan to co-develop a series of in vitro tests to aid in the early-stage drug-discovery process, the companies said last week.

Upstate Group will partner with Dundee, Scotland-based CXR to develop the drug toxicity and metabolism screens to profile compounds in various cell-based and in vitro assays, the companies said.

Financial details were not disclosed.

Cellomics Shores Up European Sales Force

Cellomics last week said that it has expanded its European training, service, and support operations, "adding new people and new programs to its repertoire of support services for Europe."

"New employees have been hired to help support our customers from the feasibility/evaluation stage all the way through to the assay development, training, and productivity stages of HCS implementation," David Sharp, Cellomics' director of European sales and services, said in a statement.

No further details were given regarding the number of new employees.

Odyssey Thera Signs Service Agreement with Lexicon Genetics

Odyssey Thera last week signed an agreement with Lexicon Genetics to characterize the pathway activity of certain Lexicon compounds in human cells, Odyssey said.

The announcement marks the fifth such service agreement for Odyssey, which "takes a pathway-based approach to drug discovery" based on its proprietary live-cell protein-fragmentation complementation assay.

Financial terms of the deal were not disclosed.

Kalypsys to Provide uHTS Screening
Tech to Florida Scripps Research Institute

Kalypsys has entered into an agreement with the Scripps Research Institute to provide Scripps with its proprietary ultra-high-throughput screening technologies, Kalypsys said recently.

Financial terms of the deal were not disclosed.

Galapagos, Celera Genomics in Gene Function Analysis Deal

Galapagos said last week that its Galadeno services division would provide services and reagents to Celera Genomics for analyzing gene function in human cells.

Under the terms of the services agreement, Galadeno will provide technology and adenoviral reagents that will enable Celera to validate potential drug targets. Galadeno will construct recombinant adenoviruses containing genes selected by Celera. The viruses will be used to introduce the genes into various cell types to evaluate their function within biological pathways, Galapagos said.

Galadeno will receive payments "related to its services and technology," Galapagos said, but further financial details were not disclosed.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.